Compare Flux Power Holdings Inc (FLUX) vs Novavax Inc (NVAX) Price & Performance

FLUX stock surged 17.58% to $0.6161, showing strong daily momentum despite a bearish technical backdrop with 17 sell signals. The company reported mixed quarterly earnings, missing estimates in Q3 2025 and Q1 2026 but beating in Q4 2025. Revenue declined to $51M in 2026 from $66M in 2025, with a net income margin of -12.48%. Recent developments include the launch of SkyEMS 3.0 AI platform and a new VP of Sales appointment, aiming to bolster growth in the energy storage sector.

Outlook is cautiously optimistic due to unanimous analyst buy ratings but tempered by profitability challenges and technical weakness. Key opportunities lie in AI-driven fleet solutions expansion, while risks include persistent losses, competitive pressure, and execution hurdles in scaling operations.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.